The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects
A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in Healthy Male and Female Subjects
Sponsor: Covance
This PHASE1 trial investigates Idiopathic Pulmonary Fibrosis and is currently completed. Covance leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Apr 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE1
Status: Unknown Status → Active Not Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Unknown Status PHASE1
▶ Show 4 earlier versions
-
May 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Oct 2018 — May 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Covance
- Sunshine Lake Pharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .